The Regulation of Dietary Supplements in the Republic of Armenia

Abstract

Sixty-one dietary supplements are currently registered in Armenia and interest in these products has been growing. In 1996, the Armenian Drug and Medical Technology Agency of the Ministry of Health adopted the “Resolution of Licensing of Dietary Supplement Products.” This resolution is based upon the Drug Law of Armenia of 1998, which excludes from registration in Armenia any drugs that are detrimental to public health due to the uncontrolled sale of such products and the lack of information about them. The Drug and Medical Technology Agency created a product database with information about registered dietary supplements' manufacturers, ingredients, and claims.

The resolution and the database demonstrate the Drug and Medical Technology Agency's dietary supplement expertise and evaluation criteria. The parameters for rejected dietary supplement applications are included and the requirements for dietary supplement labels are described. To prevent adulterated or counterfeit dietary supplements from being marketed in Armenia, special controls were introduced for some categories of dietary supplements (sedatives, hypoglycemic supplements, tonics, and arthritis supplements).

Keywords

Dietary supplements Drug law Regulatory status Label Licensing

Get full access to this article

View all access options for this article.

References

US Food and Drug Administration, Center for Food Safety and Applied Nutrition. Overview of Dietary Supplements. January 3, 2001. http://www.cfsan.fda.gov/∼dms/ds-oview.html.

Bouldin

Smith

Banahan

McCaffrey

Croom

Herbal supplement information and the consumer. Drug Inf J. 2000;34:1339–1353.

Amroyan

Zakaryan

Consumer information about herbal dietary supplements. Drugs Med. 2001;2:33–41.

US Food and Drug Administration, Center for Food Safety and Applied Nutrition. Illness and Injuries Associated with the Use of Selected Dietary Supplements. http://vm.cfsan.fda.gov/∼dms/ds-ill.html.

US Food and Drug Administration. Talk Paper. FDA Warns about GBL-related Products. May 11, 1999. http://fda.gov/bbs/topics/ANSWERS/ANS00953.2html.

Budazinski

Foster

Vandenhoek

Hanna

Aranson

An in vitro evaluation of human cytochrome p-450 3a4 inhibition by selected commercial herbal extracts and tinctures. Phytomed. 2000;7(4):273–282.

Taylor

Wilt

Probable antagonism of warfarin with green tea. Ann Pharmacother. 1999;33:426.

US Congress Senate Bill S.784. Dietary Supplement Health and Education Act of 1994.

Royal Decree on Herbal Food Products (Warenwetbesluit Kruiden-preparaten) Staatsblad 56. The Netherlands. January 31, 2001.

10.

Bryan

Coleman

Meisberger

Copmann

Issues in the regulation of dietary supplements. Drug Inf J. 2001;35:529–538.

11.

Arbeitskreis Lebensmittelchemischer Sachverstandiger der Lander und des BgW. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz. 1999;42:360–361.

12.

Drug Law of the Republic of Armenia. Yerevan, Armenia. October 8, 1998.

13.

Amirdowlat Amasyaci. Needless for Ignoramus. Moscow, Union of Soviet Socialist Republics; Nauka: 1990.

14.

World Health Organisation and Drug and Medical Technology Agency Republic of Armenia Workshop Report. The Progress in Realization of National Drug Policy in Armenia Since 1994 to 2000. Yerevan, Armenia. 2001.

15.

De Smet PAGM. Overview of herbal quality control. Drug Inf J. 1999;33:717–724.

16.

Dzulkifli

Poison Control: Traditional Medicine and the Use of Steroids as Adulterants. Malaysia: The National Poison Centre at University Sains Malaysia. http://pm.usm.my/steroids/index.html.

17.

US Food and Drug Administration. Talk Paper. FDA Warns Against Consuming Triax Metabolic Accelerator. November 11, 1999. http://fda.gov/bbs/topics/ANSWERS/ANS00984.html.

18.

Russian Federation Ministry of Health Guidance. Assessment of Certification of BADS. Moscow, Russia; 1997.

19.

World Health Organisation/Essential Drugs and Medicines/Traditional Medicine. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. Annex V. Guidelines for Levels and Kinds of Evidence to Supports Claims for Therapeutic Goods. Geneva, Switzerland: World Health Organisation. 2000.

20.

US Food and Drug Administration. Talk Paper. FDA Finalizes Rules for Claims on Dietary Supplements. Rockville, MD: US Food and Drug Administration January 5, 2000.

21.

Food Labeling; Notification Procedures for Statements on Dietary Supplements. Federal Register. 1997;62(184): 49883–49886.

22.

Kurtzweil

An FDA guide to dietary supplements. US FDA Consumer. October 1998, revised January 1999. http://vm.cfsan.fda.gov/'dms/fdsupp.html.

23.

Gabrielyan

Amroyan

Zakaryan

Adverse effects of biologically active dietary supplements. Urartu (newspaper). 2001; 10.

24.

Gabrielyan

Amroyan

Zakaryan

Consumer information about herbal dietary supplements. Golos Armenii (newspaper). March 1, 2001.